What about stomach inflammation? Listen to the doctor.

Chronic stomachitis is a common disease of the digestive system, which can cause many disorders in the lives of patients and seriously affect their quality of life. On December 24, 2022, China ‘ s Guidelines for the Treatment and Treatment of Chronic Stomach Inflammation were published in Shanghai. This is a guide that brings together the medical consensus of competent medical specialists in digestive internal medicine from all over the country and provides new basis and guidance for the treatment of chronic stomach inflammation. The following elements will be interpreted in plain and understandable language to help to better understand the key elements of the guide. I. Prevalence and high prevalence: Chronic stomach disease is common in the country and is currently close to 90 per cent based on endoscopy diagnosis. The infection rate of the H. pylori, which is around 49.6 – 55.8 per cent, is the main cause of chronic stomach disease, and therefore the incidence of chronic stomach disease is high. If you have symptoms of infection with the fungus, such as dryness, bad breath, stomach pain, etc., then improve the detection of the fungus in a timely manner. With age: The incidence of chronic atrophy of stomach disease tends to rise with age, with slightly higher prevalence among men than among women. The H. pylori infection occurs mainly in children and young people and increases the risk of chronic atrophy of stomachitis as the infection accumulates. The ageing of our population has also led to an increase in the incidence of chronic atrophy of stomachitis. So if you have chronic atrophy in your seniors, do not be too worried, improve the cholesterosomiasis test, and regulate treatment, so that you can control your condition well. In relation to the incidence of stomach cancer: The incidence of chronic atrophy of stomach disease varies considerably from country to country and from country to country, and is related to the prevalence of H. Pylori infection, the environment, genetics, diagnostic methods, etc., and to the incidence of stomach cancer. The incidence of chronic atrophy in China and Japan is higher than in the rest of the world. II. Main causes of disease and classification: H. Pylori ‘ s infection is the leading cause of chronic stomach disease, with 70 – 90 per cent of patients with a stomach mucous membrane infected with the infection, and the infection is not automatically eliminated. A high incidence of childhood infections leads to stomach inflammation, while adults are more likely to be stomach inflammation. Other causes of disease: Courage reverses, long-term use of inflammation drugs (e.g. aspirin), alcohol ingestion, etc. are also common causes, which cause light inflammation but are also classified as stomach inflammation and are relatively common in H. Pylori ‘ s vaginal stomach inflammation. Self-immunization factor: My own immune factor plays a key role in the incidence of my own immunosuppression, which is relatively rare in my country. This stomach inflammation is mainly manifested in stomach atrophy, with anti-wall cell antibodies and anti-intrafactor antibodies in the patient and, in serious cases, malignant anaemia due to vitamin B12 deficiency. Clinical behaviour is diverse and non-specific: chronic stomach disease is not particularly typical and some patients may not be ill. Patients with symptoms are characterized by symptoms of similar functional indigestion, such as abdominal pain, abdominal swelling, saturation after eating, early saturation, etc., and nearly one third of patients have two or more symptoms. The severity of the symptoms is not clearly related to what is seen in the endoscope and to the pathology grade. Simply put, you may feel abdominal pain and abdominal swelling, but the inflammation in the stomach is not as serious as you think. As stated above, if you have severe abdominal pain, abdominal abdominal abdominal abscess, etc., but your stomach and intestines are healthy, then beware that you have mental and psychological factors that can be associated with psychological stress, sleep disorders, anxiety and depression, which fall within the category of digestive heart disease and require attention. Symptoms of autoimmune gastroenteritis: Early autoimmune stomachitis is usually unsymptomatic, malignant anaemia may occur after the development of the disease, as well as neurological changes in the surroundings resulting from vitamin B12 deficiency, which also increases the risk of a combination of stomach neuroendocrine tumors of type I and other self-immunological diseases (e.g., I-diabetes, autoimmune thyroid). The majority of the elderly suffer from vitamin B12 symptoms of lack of associated nervous systems, and young patients are often diagnosed with digestive tract symptoms or iron deficiency anaemia. The endoscope diagnosis is combined with pathology: often you are treated for abdominal pain, abdominal swelling, etc., and doctors recommend that you improve your stomach examination. The endoscope diagnosis of chronic stomach inflammation is based mainly on normal white light or special imaging methods to observe mucous changes. Chronic stomach inflammation is classified as chronic non-atrophy and chronic atrophy, and, as technology develops, endoscopes can now perform electronic dyeing in addition to white light, which can significantly increase the detection of atrophy. Assessment of the state of H. Pylori infection: If you have H. Pylori infection, a preliminary assessment can also be made through an endoscope, such as the presence of permeable red, mucous swelling of the stomach mucous membranes at the time of infection. This is, of course, a preliminary assessment, and it is best that you do a carbon 13 or carbon 14 excretion test as the basis for the eradication of H. Pylori. Abbreviation, intestinal extent assessment: The lower the end mirror assessment atrophy, the greater the extent of intestinal cancer, the greater the risk. So when you do your stomach glasses, the doctor may need to take a pathological examination of your stomach to support the determination, which helps to grade you dangerously and can follow you up. Moreover, many endoscopes are now electro-chromosomalized and amplification mirrors, which allow for the observation of mucous membrane microform changes, improve the accuracy of the active detection material and reduce the number of active test blocks, a combination of which can further enhance the efficacy of the disease. Follow-up recommendations: How long will it take to review the stomach glasses? The mild atrophy of gastricitis, which is confined to the stomach atolls, does not necessarily require regular endoscopy follow-up; stomach atrophy, which involves gastric atrophy, which is examined every 1-3 years; and a closer follow-up when there are other gastric cancer risk factors. If you are unfortunately suffering from autoimmune gastric inflammation, a follow-up visit is required for no more than three years, because you are at risk of stomach cancer and tumours in the stomach and nerve. V. Individualized treatment of the principle of treatment: The treatment of chronic gastroenteritis is based on the principle of individualization, which aims at removing the causes, mitigating the symptoms, improving the response to gastromusitis and preventing complications. Unsatisfied, H. pylori negative chronic non-atrophyic stomachitis generally does not require special treatment, but chronic atrophy of stomachitis, especially for those who are serious or who are associated with heterogeneity, must be careful to prevent malformation. Dietary and lifestyle adjustments: Dietal changes and lifestyle adjustments are part of the treatment, such as avoiding chronic and intensive use of gastropharmaceuticals and reducing the intake of coffee, alcohol and tobacco. For the treatment of cholesterol reverses: If you are chronic gastric inflammation with cholesterol, you can use a gastric muccultative protection agent (e.g. magnesium aluminum, gastrointestinal agonist and/or antiacids) combined with choreography, with conditions for short-term oxychoric acids. Medicines: If you take NSAID or aspirin for a long time, these can cause long-term damage to the gastric mucous membranes, and if you take these drugs and have more serious digestive symptoms, you need to assess whether you can stop using them, and if you really need to take them for a long-term period, then you need to use antiacids or gastric mucous membranes to protect your stomach mucous membranes. Symptoms: In addition to the obvious cause, we can select drugs based on the symptoms, using gastric mucous membranes, antiacidants, H2RA, PPI; gastrointestinal precipitating and/or digestive enzyme formulations such as diarrhea; and available neurotransmitting drugs with mental factors. Some Chinese medicine can also be combined, and our traditional Chinese medicine can be effective in mitigating digestive symptoms and may improve stomach mucous pathologies, but there is no evidence of high-quality clinical research, due to the lack of clinical research. H. Pylori Eradication: H. Pylori Positive Chronic Stomachitis, with or without symptoms and complications, should generally be eradicated, unless there are countervailing factors (e.g. disease associated with the patient, high rate of re-infection in the community, etc.). Eradicating H. Pylori can slow down the atrophy of the gastric mucous membranes and intestinal development and reduce the risk of stomach cancer. We recommend a four-prong (PPI + americant + 2 antibacterial drugs, 14 days of treatment) and a two-protocol high-dose programme, with a combination of antibiotics choosing to refer to local resistance rates and personal antibiotic use history, and acids choosing a PPI or P-CAB that is less affected by CYP2C19 genetic polymorphism. VIII. Transferred to factors affecting the prevention of cancer: advances in chronic stomachitis (especially chronic atrophy) are influenced by such factors as genetics, H. pylori infection, diet, habits, age, etc., increased risk of stomach cancer associated with heterogeneity, and the combination of a combination of factors, “attitudinal age”, can reflect the aging of stomach mucous cells. Repeated H.pylori infections, bad eating habits can increase atrophy and intestinal life, chronic atrophy of stomachitis can develop into stomach cancer, low-grade hetogenic growth is mostly reversible, and most chronic non-atrophysic cases are stable, especially those without H.pylori ‘ s continuous infection. “Attendance age” may require closer follow-up with the age difference. Prevention of cancer: The eradication of H. Pylori can mitigate the inflammation of inflammation to atrophy, intestinalization, heteogeneity and reduction of the incidence of stomach cancer. The best intervention time is prior to a change in stomach cancer, which has a better effect on the prevention of mild chronic atrophy of stomach cancer, as well as the effects of stomach cancer on the prevention of abdominal cancer following the removal of stomach cancer in the inner mirror, and in countries such as ours in East Asia, which meet health economics standards. Some vitamins (e.g., folic acid, vitamin B12), trace elemental selenium or garlic may reduce the incidence of stomach cancer, and appropriate supplementation of folic acid at low levels in the body can improve chronic atrophy of gastropathological tissue. ix. The issue of intestinal reversals of contentious issues: intestinal reversals can be natural, the eradication of H. Pylori can also be reversed, and the intervention of some medicines (e.g., sieves, vitamins, Morodin, etc.) also shows the effect of intestinal reversals. Aspirin use: Patients suffering from pre- gastro-cancer diseases and requiring long-term service with aspirin for cardiovascular diseases may reduce the risk of stomach cancer at low doses per day, but aspirin may have serious adverse effects and is not recommended for routine use in stomach cancer prevention, although low doses of aspirin may be considered for use in the prevention of stomach cancer for safety and benefit of people with combined underlying diseases. Ethylene cyclic oxide – 2 inhibitors: although they may reduce the risk of progress of stomach cancer or pre-cancer disease, they are not recommended for use in the prevention of stomach cancer or pre-cancer disease, given the low number of studies, the low quality of the evidence and the adverse effects. We have developed a more comprehensive and in-depth understanding of chronic stomach disease through the interpretation of the updated guidelines for chronic stomach disease treatment in China, 2022. This helps patients to become more aware of their condition and to cooperate actively in their treatment. It also enables people to take effective preventive measures in their daily lives to protect their stomach health. The addition of the relevant knowledge of cholesterocella in the article created a general science article on the subject of chronic non-abbreviated stomachitis, which provides some advice on the writing of a general science article.